Homogeneous Catalytic Hydrogenation of Amides to Amines
作者:Jacorien Coetzee、Deborah L. Dodds、Jürgen Klankermayer、Sandra Brosinski、Walter Leitner、Alexandra M. Z. Slawin、David J. Cole-Hamilton
DOI:10.1002/chem.201204270
日期:2013.8.12
Hydrogenation of amides in the presence of [Ru(acac)3] (acacH=2,4‐pentanedione), triphos [1,1,1‐tris‐ (diphenylphosphinomethyl)ethane] and methanesulfonic acid (MSA) produces secondary and tertiary amines with selectivities as high as 93 % provided that there is at least one aromatic ring on N. The system is also active for the synthesis of primary amines. In an attempt to probe the role of MSA and
在[Ru(acac)3 ](acacH = 2,4-戊二酮),三[[1,1,1-三(二苯基膦甲基)乙烷]]和甲磺酸(MSA)的存在下进行酰胺加氢生成仲胺和叔胺如果在N上至少有一个芳环,则其选择性高达93%。该系统对伯胺的合成也具有活性。为了探索MSA的作用和反应机理,已经从[Ru(acac)3 ],三醇和MSA或[RuX(OAc)(triphos)]的反应中制备了一系列甲磺酸钠络合物。 (X = H或OAc)或[RuH 2(CO)(triphos )]与MSA。晶体学表征复合物包括:[茹(OAC-κ 1 O)2(H 2O)(triphos)],[Ru(OAc‐κ 2 O,O')(CH 3 SO 3 ‐κ 1 O)(triphos )],[Ru(CH 3 SO 3‐ κ 1 O)2(H 2 O)(三膦)]和[孺2(μ-CH 3 SO 3)3(三磷酸)2 ] [CH 3 SO 3 ],而其他复合物,例如[茹(OAC-κ
SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS
申请人:GLAXOSMITHKLINE LLC
公开号:US20150152108A1
公开(公告)日:2015-06-04
The present invention relates to novel substituted bridged urea compounds, corresponding related analogs, pharmaceutical compositions and methods of use thereof. Sirtuin-modulating compounds of the present invention may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders, which include, but are not limited to, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. The present invention also related to compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.
Synthesis and characterization of N-heterocyclic carbene-palladium(<scp>ii</scp>) chlorides-1-methylindazole and -1-methylpyrazole complexes and their catalytic activity toward C–N coupling of aryl chlorides
作者:Xiao-Yun Zhao、Quan Zhou、Jian-Mei Lu
DOI:10.1039/c6ra02556k
日期:——
series of N-heterocycliccarbene-palladium(II) chlorides-1-methylindazole and -1-methylpyrazole complexes was successfully synthesized and fully characterized by X-ray single crystal diffraction. In addition, initial investigations of their catalytic activity showed that they were efficientcatalysts in the C–N coupling of primary and secondary amines with aryl chlorides at low catalyst loadings.
Phosphoryl chloride-mediated solvent-free synthesis of N-aryl-substituted azacycles from arylamines and cyclic ethers
作者:Van Hieu Tran、Minh Thanh La、Hee-Kwon Kim
DOI:10.1016/j.tetlet.2019.06.019
日期:2019.7
cyclic ethers is described. In this method, the combination of POCl3 and DBU is crucial for conversion of arylamines and cyclic ethers to five- and six-membered azacycles. Without solvent, a variety of N-aryl-substituted, five-membered azacycles (pyrrolidines, 2-methylpyrrolidines, and piperidine) and six-membered azacycles (isoindolines and tetrahydroisoquinolines) are synthesized in high yields. This
[EN] HETEROCYCLE CONTAINING STAT INHIBITORS AND COMPOSITIONS<br/>[FR] HÉTÉROCYCLES CONTENANT DES INHIBITEURS STAT ET COMPOSITIONS
申请人:JANPIX LTD
公开号:WO2021178841A1
公开(公告)日:2021-09-10
Provided herein are compounds and pharmaceutical compositions comprising said compounds that are useful for the inhibition of Signal Transducer and Activator of Transcription 5a and 5b (STAT5). Furthermore, the subject compounds and compositions are useful for the treatment of cancer, such as, for example, breast cancer and pancreatic cancer.